Andrea Olariu, MD, PhDInterim CEO
Andrea Olariu, MD, PhD is the Interim CEO of Medicines360. Dr. Olariu joined Medicines360 in 2010 as the Vice President of Clinical Affairs. She held positions with increasing responsibility as the General Manager, Chief Medical Officer and served as Chief Operating Officer of Medicines360 from 2018 – 2020. Dr. Olariu has led the clinical and regulatory strategy resulting in successful FDA approvals of the company’s hormonal IUD, LILETTA.
Dr. Olariu has extensive experience in designing and conducting clinical trials from proof of concept to large pivotal Phase 3 studies and in leading development of new products. Prior to Medicines360, Andrea developed and implemented clinical/medical and regulatory strategies for several medical devices that received approval in the US, Canada, and the European Union.
Prior to moving to the United States, Dr. Olariu worked for over 15 years in academia, as an Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and a Senior Lecturer of Immunology at the University of Medicine and Pharmacy, Timisoara in Timisoara, Romania.
Dr. Olariu has authored over 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.